ClinicalTrials.Veeva

Menu

Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients

B

Bnai Zion Medical Center

Status

Unknown

Conditions

Adrenal Insufficiency
Adrenal Cancer

Treatments

Diagnostic Test: Cosyntropin stimulation test

Study type

Interventional

Funder types

Other

Identifiers

NCT03083834
0006-17-BNZ

Details and patient eligibility

About

In mitotane treated patients, serum cortisol cannot be used to diagnose hypoadrenalism, since mitotane increases cortisol binding globulin levels (CBG), artificially raising total cortisol. Salivary free cortisol (SC) is not affected by CBG alterations, and reflects the free serum cortisol.

In the current study, investigators will assess serum and SC responses during low-dose cosyntropin stimulation test in healthy volunteers, mitotane-induced hypoadrenal patients on steroid replacement therapy and in patients who suffer from hypoadrenlism caused from other etiology. Investigators will compare results between groups and try to demonstrate the superiority of SC in assessing adrenal function in mitotane treated patients.

Full description

80-90% of circulating cortisol is bound to cortisol binding globulin (CBG) or transcortin, whereas only 3-10% is in the free state. Salivary free cortisol (SC) is an index of plasma free cortisol. In previous studies it was shown that in low-dose cosyntropin stimulation test, SC increases significantly in normal but not in hypoadrenal patients. It was suggested that dynamic assessment of the SC response to ACTH may be particularly helpful whenever the measurement of serum cortisol is complicated by increased or decreased CBG levels.

Adrenocortical carcinoma (ACC) is a rare malignancy with a heterogeneous presentation and a variable but generally poor prognosis. Mitotane is the main drug for ACC treatment and it plays a role both in adjuvant treatment after complete resection and in recurrent, inoperable and/or metastatic ACC. Mitotane blocks adrenocortical steroid synthesis and also exerts a specific cytotoxic effect on adrenocortical cells. Mitotane induces adrenal insufficiency, requiring hydrocortisone replacement therapy. In mitotane treated patients, serum cortisol cannot be used to diagnose hypoadrenalism, since mitotane increases CBG levels, artificially raising total cortisol. SC is not affected by CBG alterations, and reflects the free serum cortisol and may be more accurate in diagnosing hypoadrenalism in mitotane treated patients.

In the current study, investigators will assess serum and SC responses during low-dose cosyntropin stimulation test in healthy volunteers, mitotane-induced hypoadrenal patients on steroid replacement therapy and in patients who suffer from hypoadrenlism caused from any other etiology. Investigators will compare results between groups and try to demonstrate the superiority of SC in assessing adrenal function in mitotane treated patients.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • mitotane treated
  • known hypoadrenlism

Exclusion criteria

  • pregnancy

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

50 participants in 3 patient groups

healthy subjects
Experimental group
Description:
low-dose cosyntropin stimulation test
Treatment:
Diagnostic Test: Cosyntropin stimulation test
hypoadrenal mitotane treated patients
Experimental group
Description:
low-dose cosyntropin stimulation test
Treatment:
Diagnostic Test: Cosyntropin stimulation test
hypoadrenal no-mitotane treated patients
Experimental group
Description:
low-dose cosyntropin stimulation test
Treatment:
Diagnostic Test: Cosyntropin stimulation test

Trial contacts and locations

1

Loading...

Central trial contact

Leonard Saiegh, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems